% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Schlenk:128269,
      author       = {R. F. Schlenk and S. Kayser and L. Bullinger and G. Kobbe
                      and J. Casper and M. Ringhoffer and G. Held and P. Brossart
                      and M. Lübbert and H. R. Salih and T. Kindler and H. A.
                      Horst and G. Wulf and D. Nachbaur and K. Götze and A.
                      Lamparter and P. Paschka and V. I. Gaidzik and V. Teleanu
                      and D. Späth and A. Benner$^*$ and J. Krauter and A. Ganser
                      and H. Döhner and K. Döhner},
      collaboration = {G. A. S. Group},
      title        = {{D}ifferential impact of allelic ratio and insertion site
                      in {FLT}3-{ITD}-positive {AML} with respect to allogeneic
                      transplantation.},
      journal      = {Blood},
      volume       = {124},
      number       = {23},
      issn         = {1528-0020},
      address      = {Stanford, Calif.},
      publisher    = {HighWire Press},
      reportid     = {DKFZ-2017-04286},
      pages        = {3441 - 3449},
      year         = {2014},
      abstract     = {The objective was to evaluate the prognostic and predictive
                      impact of allelic ratio and insertion site (IS) of internal
                      tandem duplications (ITDs), as well as concurrent gene
                      mutations, with regard to postremission therapy in 323
                      patients with FLT3-ITD-positive acute myeloid leukemia
                      (AML). Increasing FLT3-ITD allelic ratio (P = .004) and IS
                      in the tyrosine kinase domain 1 (TKD1, P = .06) were
                      associated with low complete remission (CR) rates. After
                      postremission therapy including intensive chemotherapy (n =
                      121) or autologous hematopoietic stem cell transplantation
                      (HSCT, n = 17), an allelic ratio ≥ 0.51 was associated
                      with an unfavorable relapse-free (RFS, P = .0008) and
                      overall survival (OS, P = .004); after allogeneic HSCT (n =
                      93), outcome was significantly improved in patients with a
                      high allelic ratio (RFS, P = .02; OS, P = .03), whereas no
                      benefit was seen in patients with a low allelic ratio (RFS,
                      P = .38; OS, P = .64). Multivariable analyses revealed a
                      high allelic ratio as a predictive factor for the beneficial
                      effect of allogeneic HSCT; ITD IS in TKD1 remained an
                      unfavorable factor, whereas no prognostic impact of
                      concurrent gene mutations was observed. The clinical trials
                      described herein were previously published or are registered
                      as follows: AMLHD93 and AMLHD98A, previously published; AML
                      SG 07-04, ClinicalTrials.gov identifier #NCT00151242.},
      keywords     = {FLT3 protein, human (NLM Chemicals) / fms-Like Tyrosine
                      Kinase 3 (NLM Chemicals)},
      cin          = {C060},
      ddc          = {610},
      cid          = {I:(DE-He78)C060-20160331},
      pnm          = {313 - Cancer risk factors and prevention (POF3-313)},
      pid          = {G:(DE-HGF)POF3-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:25270908},
      doi          = {10.1182/blood-2014-05-578070},
      url          = {https://inrepo02.dkfz.de/record/128269},
}